Conference Coverage

Eliminating Threat of Hepatitis A in Hemophiliacs

Published in Vaccine Weekly, March 20th, 1995

That hemophiliac patients are at risk for hepatitis A was among the topics discussed at the Liver Disease in Hemophilia conference March 3-5, 1995, in Atlanta, Georgia.

The topic was especially timely because just a week earlier the U.S. Food and Drug Administration (FDA) had licensed SmithKline Beecham Biologicals (Philadelphia, Pennsylvania) to market Havrix, (hepatitis A vaccine, inactivated) the company's hepatitis A vaccine.

"Hemophiliac patients are at risk for hepatitis A. We don't know the extent of that risk," stated Bruce Evatt, M.D., chief, Hematologic Diseases Branch, U.S. Centers for Disease Control and Prevention (CDC), one of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1995-03-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry